Certain factors that are driving the market growth include the increasing awareness about bladder diseases and available therapies, innovations in drug development, and increasing healthcare expenditure.
Based on the data from the International Agency for Research on Cancer 2018, bladder cancer is the sixth most commonly diagnosed cancer among males and the ninth leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. However, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations. Also, the rise of immunotherapy therapies in cancer treatment has rekindled interest in eligible patients as it is a recently developed treatment modality, and has lower side-effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management. Therefore, the increasing awareness about bladder cancer and related therapies is fuelling the growth of the North American bladder cancer therapeutics and diagnostics market.
However, the accuracy of diagnostic tests like urine cytology for identifying bladder cancer is considerably low, particularly in asymptomatic patients with no history of bladder cancer. The symptoms for bladder cancer, like with most other cancers, manifest completely only in advanced stages, and early stages have no peculiar symptoms, which can assist in patient differentiation. High rate of failure in the early detection of bladder cancer is a direct outcome of this limitation. Therefore, the asymptomatic nature of bladder cancer is restricting the growth of the North American bladder cancer therapeutics and diagnostics market.
Key Market Trends
Chemotherapy, by Therapeutics, is Expected to Hold a Significant Share Over the Forecast Period
Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy.
The most common drugs used, when administered along with radiation, are Cisplatin, Mitomycin, 5-Fluorouracil, also these in combination. Drugs used without radiation therapy are Methotrexate, Vinblastine, Doxorubicin, and Cisplatin. Some other drugs also used in bladder cancer are Gemcitabine, Paclitaxel, Carboplatin, Ifosfamide, Thiotepa, Pemetrexed, and Docetaxel. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. There exists a void in the market. The increasing aging population and the high incidence of bladder cancer among the population are expected to drive the market over the forecast period.
The North American bladder cancer therapeutics and diagnostics market is highly competitive and consists of a number of major players. Companies, like AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Sanofi SA, and Johnson & Johnson (Janssen Pharmaceutical) hold the substantial market share in the North American bladder cancer therapeutics and diagnostics market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support